Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upfront autologous HSCT versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis
2019-004718-32Phase 4Active
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of autologous hematopoietic stem cells in diffuse cutaneous systemic sclerosis (dcSSc) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Event-free survival. Started Oct 2020; status: active.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on 2019-004718-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004718-32.